Three New Next Generation Cardiac Marker Products Launched

A Swiss company offers three new cardiac marker test kits for point-of-care (POC) settings.

The next generation products are Troponin I--a single-analyte, improved sensitivity Troponin I (TnI) test, Cardio2--a two analyte panel consisting of the new Troponin I and B-type natriuretic peptide (BNP), as well as Cardio3--a three analyte panel consisting of the new Troponin I, BNP and Creatine Kinase, Muscle and Brain (CK-MB).

Alere International (Morges, Switzerland) launched the three new cardiac marker test kits. By offering this improved sensitivity troponin assay on panels that simultaneously test other cardiac markers at the POC, these products will allow emergency physicians to make better chest pain/shortness-of-breath patient disposition decisions much more rapidly.

When used in a rapid serial draw algorithm, the panel results can identify healthy patients earlier, allowing them to go home sooner and physicians to focus their time on only those patients in greatest need. All three products are designed for use on the Triage Meter.

The tests are now available for commercial sale in Europe, Australia, and New Zealand and will soon be available in other countries around the world.

Alere is the new global brand adopted by many of the diagnostic and health management businesses of Inverness Medical Innovations (Waltham, MA, USA).

Related Links:
Alere International
Inverness Medical Innovations